

## SOUTH SUDAN INACTIVATED POLIO VACCINE (IPV) SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> South Sudan															
<b>2. Grant Number:</b> 1518-SDS-25b-X / 15-SDS-08h-Y															
<b>3. Date of Decision Letter:</b> 5 February 2015															
<b>4. Date of the Partnership Framework Agreement:</b> 24 June 2013															
<b>5. Programme Title:</b> NVS, IPV Routine															
<b>6. Vaccine type:</b> Inactivated Polio Vaccine (IPV)															
<b>7. Requested product presentation and formulation of vaccine<sup>1</sup>:</b> Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID															
<b>8. Programme Duration<sup>2</sup>:</b> 2015 - 2018															
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b> <i>Please note that endorsed or approved amount for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i> <table border="1" style="margin: 10px auto; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 15%;"></th> <th style="width: 15%;">2015</th> <th style="width: 15%;">2016</th> <th style="width: 15%;">2017</th> <th style="width: 15%;">Total<sup>3</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: left;">Programme Budget (US\$)</td> <td>US\$328,500</td> <td>US\$522,500</td> <td>US\$421,500</td> <td>US\$1,272,500</td> </tr> </tbody> </table>		2015	2016	2017	Total <sup>3</sup>	Programme Budget (US\$)	US\$328,500	US\$522,500	US\$421,500	US\$1,272,500					
	2015	2016	2017	Total <sup>3</sup>											
Programme Budget (US\$)	US\$328,500	US\$522,500	US\$421,500	US\$1,272,500											
<b>10. Vaccine Introduction Grant:</b> US\$341,500															
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b> <table border="1" style="margin: 10px auto; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 50%;">Type of supplies to be purchased with Gavi funds in each year</th> <th style="width: 25%;">2015</th> <th style="width: 25%;">2016</th> </tr> </thead> <tbody> <tr> <td style="text-align: left;">Number of IPV vaccines doses</td> <td>159,900</td> <td>254,400</td> </tr> <tr> <td style="text-align: left;">Number of AD syringes</td> <td>154,500</td> <td>241,400</td> </tr> <tr> <td style="text-align: left;">Number of safety boxes</td> <td>1,700</td> <td>2,675</td> </tr> <tr> <td style="text-align: left;">Annual Amounts (US\$)</td> <td>US\$328,500</td> <td>US\$522,500</td> </tr> </tbody> </table>	Type of supplies to be purchased with Gavi funds in each year	2015	2016	Number of IPV vaccines doses	159,900	254,400	Number of AD syringes	154,500	241,400	Number of safety boxes	1,700	2,675	Annual Amounts (US\$)	US\$328,500	US\$522,500
Type of supplies to be purchased with Gavi funds in each year	2015	2016													
Number of IPV vaccines doses	159,900	254,400													
Number of AD syringes	154,500	241,400													
Number of safety boxes	1,700	2,675													
Annual Amounts (US\$)	US\$328,500	US\$522,500													
<b>12. Procurement agency:</b> UNICEF.															
<b>13. Self-procurement:</b> Not applicable.															

<sup>1</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>2</sup> This is the entire duration of the programme.

<sup>3</sup> This is the total amount endorsed by Gavi for 2015 to 2017.

<sup>4</sup> This is the amount that Gavi has approved

**14. Co-financing obligations: N/A**

Gavi's usual co-financing requirements do not apply to IPV. However, South Sudan is encouraged to contribute to vaccine and/or supply costs for IPV.

**15. Operational support for campaigns: N/A**

**16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:**

Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	To be agreed with Gavi Secretariat

**17. Financial Clarifications:** Not applicable

**18. Other conditions:**

If South Sudan envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to South Sudan.

Please provide copy of insurance policy as proof that vaccines and devices are insured as stipulated in the Partnership Framework Agreement.

**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes

5 February 2015